Wearable nasal technology

Rhinomed is a global medical device company enhancing respiration, sleep, diagnosis of upper respiratory disease and nasal drug delivery.

Find out more

Introducing RHINOSWAB

The world’s most comfortable nasal swab for COVID-19 and upper respiratory pathogens including influenza and RSV.

Find out more about RHINOSWAB

Rhinomed
knows noses

Rhinomed is a wearable nasal technology company that seeks to radically improve the way you breathe, sleep, maintain your health, diagnose disease and take medication.

We create medical devices that are used by millions of people globally.

With a pipeline of compelling innovation focused on clear unmet clinical needs, we invite you to experience firsthand the difference Rhinomed can make to your way of life.

COVID-19 testing

Rhinoswab changes the way you collect a sample for diagnosis. Rhinoswab standardises the sampling process for COVID-19 and flu, making it easy and comfortable for clinician and patient alike.

Sport

Breathing clearly and easily is a key element in aerobic activity. Turbine is designed to assist athletes to overcome nasal obstruction and congestion by increasing airflow by up to 38%.

Snoring

About half of the population snore. Mute dilates the nasal passages making nasal breathing easier, reducing mouth breathing and helping you to breathe more, snore less and sleep better.

Congestion

A novel vapour delivery technology, Pronto Clear helps to clear a stuffy nose naturally through the delivery of a proprietary essential oil formulation.

Sleep

Pronto Sleep uses our patented delivery technology to deliver a proprietary essential oil formulation that will help you to relax and sleep better naturally.

Clinical programs

Rhinomed’s wearable nasal technology supports a wide range of applications from stenting to diagnosis and nasal drug delivery.

News

  • Rhinoswab Secures European CE Mark
    Rhinomed is pleased to announce it has been advised by Medical Device Safety Service GmbH (MDSS) that an Authorized Representative’s Mandate according to the EU Regulation 2017/745 (MDR) is in … Read more
  • Appointment of Non Executive Director
    Rhinomed is pleased to announce the appointment of Associate Professor John McBain AO as a Non Executive Director of the Company, effective immediately. Assoc. Prof. McBain is the former Head … Read more
  • Key Studies Confirm Rhinoswab’s Superior Performance
    Rhinomed is pleased to report an important update on its Rhinoswab™ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal … Read more
  • Rhinomed R&D Refund
    Rhinomed is pleased to announce that the Australian Taxation Office has of today’s date refunded the R&D tax incentive amount in respect of the FY20 income tax year. The Company … Read more
  • Rhinomed Releases Half Year Results
    Rhinomed is pleased to provide its report for the half year ended 31 December 2020. Commenting on the results, Rhinomed’s CEO Michael Johnson said “2020 produced unheralded uncertainty in all … Read more
  • Rhinoswab Detects SARS-CoV-2 in Doherty Institute rt-PCR STudy
    Rhinomed is pleased to report positive data from its lab-based spiking study of Rhinomed’s new Rhinoswab conducted at the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of The Peter Doherty … Read more
See all news articles